Collapse all
The Business Model Canvas reveals a high-specialization diagnostic tool that shifts male infertility from symptomatic observation to molecular diagnosis. Success depends on integrating into existing clinical pathology workflows and targeting a niche but high-value patient segment with idiopathic asthenozoospermia.
3 Reference Laboratories Partnerships with LabCorp or Quest Diagnostics to handle high-throughput sample processing and distribution. Academic Medical Centers Collaborations with institutions like the Mayo Clinic for clinical validation and patient recruitment. Genetic Sequencing Providers Outsourcing the actual NGS (Next-Generation Sequencing) to specialized genomic platforms to reduce capital expenditure. 3 Assay Validation Developing and validating the specific primer sets and bioinformatics pipeline to accurately detect biallelic TEX44 variants. Clinical Evidence Generation Conducting retrospective and prospective studies to correlate TEX44 variants with specific mitochondrial sheath defects. Regulatory Approval Navigating FDA or CLIA/CAP certification to ensure the test is legally marketable as a clinical diagnostic. 3 Genetic Markers Proprietary knowledge of the TEX44-CPT1B axis and the specific biallelic variants associated with asthenozoospermia. Bioinformatics Pipeline Custom software to analyze WES or targeted panel data specifically for mitochondrial sheath assembly markers. Medical Advisory Board Expert urologists and reproductive endocrinologists to guide clinical adoption and interpretation. 3 Molecular Diagnosis Provides a definitive genetic cause for idiopathic asthenozoospermia, replacing 'unexplained' labels with a molecular diagnosis. Precision Counseling Allows clinicians to provide accurate genetic counseling regarding the heritability of sperm motility defects. Targeted Treatment Path Identifies patients who will not respond to general motility-boosting therapies, directing them immediately to ICSI or other interventions. 2 B2B Clinical Integration Establishing long-term service agreements with fertility clinics and pathology labs. Physician Education Providing CME-accredited webinars and whitepapers to educate urologists on the TEX44-CPT1B axis. 3 Diagnostic Lab Networks Integrating the test into the existing test menus of large-scale labs like LabCorp. Reproductive Endocrinology Clinics Direct referral paths from fertility specialists to the diagnostic panel. Medical Journals Publishing validation data in journals like 'Fertility and Sterility' to drive clinical awareness. 3 Idiopathic Asthenozoospermia Patients Men with severely impaired sperm motility who have no known cause for their infertility. Clinical Pathology Labs Labs seeking to expand their genetic infertility panels to increase their diagnostic offering. Tertiary Care Centers High-volume centers like the Mayo Clinic that handle complex, unexplained infertility cases. 3 R&D and Validation Costs associated with optimizing the genetic panel and conducting clinical trials. Regulatory Compliance Fees and operational costs for maintaining CLIA/CAP certification and FDA filings. Sequencing Costs Variable costs per sample for DNA extraction and NGS sequencing. 2 Per-Test Fee A fixed price charged per patient sample processed through the TEX44-CPT1B panel. Licensing Agreements Licensing the proprietary panel design to global diagnostic labs for a royalty per test. The idea identifies specific B2B partners like LabCorp and Mayo Clinic, making it appropriate to map the value proposition and revenue streams. · Generated 2026-09-05 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated